Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Division of General Surgery, Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
BJS Open. 2018 Dec 5;3(1):85-94. doi: 10.1002/bjs5.50115. eCollection 2019 Feb.
Pancreatic cancer surgery is increasingly regionalized in high-volume centres. Provision of adjuvant chemotherapy in the same institution can place a burden on patients, whereas receiving adjuvant chemotherapy at a different institution closer to home may create disparities in care. This study compared long-term outcomes of patients with pancreatic adenocarcinoma receiving adjuvant chemotherapy at the institution where they had undergone surgery with outcomes for those receiving chemotherapy at a different institution.
This was a population-based study of patients receiving adjuvant chemotherapy after resection of pancreatic adenocarcinoma performed at ten designated hepatopancreatobiliary centres in Ontario, Canada, between 2004 and 2014. Patients were divided into those receiving chemotherapy at the same institution as surgery or a different institution from where surgery was performed. The primary outcome was overall survival (OS). Multivariable Cox regression assessed the association between OS and each chemotherapy group, adjusted for potential confounders.
Of 589 patients, 374 63·5 per cent) received adjuvant chemotherapy at the same institution as surgery. After adjusting for age, sex, co-morbidity, socioeconomic status, rural living, tumour stage, margin positivity and year of surgery, the location of adjuvant chemotherapy was not independently associated with OS (hazard ratio 1·03, 95 per cent c.i. 0·85 to 1·24). For patients who underwent chemotherapy at a different institution, mean travel distance to receive chemotherapy was less (22·9 km) than that needed for surgery (106·7 km).
After pancreatectomy for pancreatic adenocarcinoma at specialized hepatopancreatobiliary surgery centres, OS was not affected by the location of the centre delivering adjuvant chemotherapy. Receiving this treatment in a local centre reduced patients' travel burden.
胰腺癌手术在高容量中心日益区域化。在同一机构提供辅助化疗可能会给患者带来负担,而在离家较近的不同机构接受辅助化疗可能会导致治疗差距。本研究比较了在进行手术的机构接受辅助化疗的胰腺腺癌患者与在不同机构接受化疗的患者的长期结局。
这是一项在加拿大安大略省十个指定的肝胆胰中心进行的胰腺腺癌切除术后接受辅助化疗的患者的基于人群的研究。患者分为在手术机构或手术机构以外的机构接受化疗的两组。主要结局是总生存(OS)。多变量 Cox 回归评估了 OS 与每个化疗组之间的关联,同时调整了潜在混杂因素。
在 589 名患者中,有 374 名(63.5%)在与手术相同的机构接受辅助化疗。在调整年龄、性别、合并症、社会经济地位、农村居住、肿瘤分期、边缘阳性和手术年份后,辅助化疗的位置与 OS 无独立关联(风险比 1.03,95%置信区间 0.85 至 1.24)。对于在不同机构接受化疗的患者,平均旅行距离(22.9 公里)小于手术所需距离(106.7 公里)。
在专门的肝胆胰外科中心进行胰腺腺癌手术后,OS 不受提供辅助化疗的中心位置的影响。在当地中心接受这种治疗可减轻患者的旅行负担。